In 2024, Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) achieved a net profit of 1.424 billion yuan, an increase of 121.08% year-on-year.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) released its 2024 annual performance report. The company's total operating income for 2024 was 3.558 billion yuan, a year-on-year increase of 76.29%. The net profit attributable to the owners of the parent company was 1.424 billion yuan, a year-on-year increase of 121.08%. The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 1.352 billion yuan, a year-on-year increase of 122.96%. The basic earnings per share were 3.16 yuan. The company's core product, Fomepizole Methanesulfonate tablets, was renewed in the national medical insurance catalog during the reporting period. The product sales continued to grow, and the company effectively implemented a number of cost reduction and efficiency improvement measures, strictly controlling various costs and expenses. The company's operating income for 2024, as well as the net profit attributable to the owners of the parent company and the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses, all achieved significant year-on-year growth.